Chronic Lymphocytic Leukemia (DBCOND0028332)

Identifiers

Synonyms
Chronic Lymphatic Leukemia / Chronic Lymphoid Leukemia / Chronic Lymphocytic Leukaemia / Chronic Lymphoid Leukaemia / CLL / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia (CLL) / Chronic Lymphocytic Leukemias / Leukaemias chronic lymphocytic / Chronic lymphocytic leukemia / Chronic Leukemia, Lymphocytic / Chronic lymphocytic leukemia of B-cell type not having achieved remission / Chronic lymphocytic leukemia of B-cell type / B-cell chronic lymphocytic leukaemia / B-cell chronic lymphocytic leukemia / Leukemia lymphocytic chronic / Lymphoid leukaemia, chronic / Chronic lymphoid leukemia, disease (disorder) / Lymphoid leukemia, chronic / Chronic lymphatic leukaemia / Leukaemia lymphocytic chronic / Chronic lymphocytic leukaemia NOS / Chronic lymphocytic leukemia, morphology (morphologic abnormality) / Leukemia, Lymphocytic, Chronic, B-Cell

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Acalabrutinib
A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.
Alemtuzumab
A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Bendamustine
An antineoplastic nitrogen mustard agent used in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy.
Chlorambucil
A chemotherapy agent used in the management of chronic lymphocytic leukemia and malignant lymphomas.
Cladribine
A purine antimetabolite used to treat Multiple Sclerosis (MS) and hairy cell leukemia.
Cyclophosphamide
A nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.
Hyaluronidase (ovine)
A purified form of sheep hyaluronidase enzyme used as an adjunct in subcutaneous rehydration therapy and to increase absorption of other drugs and radiopaque imaging agents.
Ibrutinib
An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.
Mechlorethamine
An antineoplastic agent used to treat Hodgkin's disease, lymphosarcoma, and chronic myelocytic or lymphocytic leukemia.
Ofatumumab
An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
Pentostatin
An adenosine deaminase inhibitor used to treat hairy cell leukemia.
Pirtobrutinib
A kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy.
Rituximab
A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
Venetoclax
A BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia.
Vincristine
A vinca alkaloid used to treat acute leukemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis.
Zanubrutinib
A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT04407845
Atrial Fibrillation in Patients Receiving IbrutinibNo drug interventionsNot AvailableNot Availableunknown_status
NCT02020109
Evaluation of Splenic Irradiation in Chronic Lymphatic LeukemiaNo drug interventionsNot AvailableNot Availablewithdrawn
NCT01246557
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatmenttreatment1 / 2completed
NCT02802943
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLLtreatment2completed
NCT01809847
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantationtreatment2completed
NCT03204188
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT06508775
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesotherNot Availablerecruiting
NCT03766763
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage atreatment2active_not_recruiting
NCT03804372
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamidetreatment2active_not_recruiting
NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioningtreatment2recruiting
NCT01518959
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseasestreatment3terminated
NCT04608318
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)treatment3active_not_recruiting
NCT04515238
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLtreatment2active_not_recruiting
NCT03787264
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLLtreatment2completed
NCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancerstreatment1active_not_recruiting
NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignanciestreatment1 / 2completed
NCT04883749
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLtreatment2active_not_recruiting
NCT05350826
Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic LeukemiaNo drug interventionsotherNot Availablerecruiting
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)treatment2recruiting
NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyNot AvailableNot Availablerecruiting
NCT06651970
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failureother4not_yet_recruiting
NCT02267590
Tissue Collection for Biomarkers Determining Resistance to IbrutinibNo drug interventionsNot AvailableNot Availableunknown_status
NCT03582098
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandNot AvailableNot Availablecompleted
NCT02164071
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesNo drug interventionsNot AvailableNot Availablecompleted
NCT00802737
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)treatment4completed
NCT01446900
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphomatreatment2terminated
NCT01805375
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell MalignanciesNo drug interventionstreatment1completed
NCT01127542
RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trialtreatment2terminated
NCT00410163
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patientstreatment2completed
NCT01678430
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatmenttreatment3unknown_status
NCT00824265
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemiatreatment3completed
NCT02933320
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemiatreatment1 / 2completed
NCT01110031
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjectsother1completed
NCT01039376
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapytreatment3terminated
NCT00292760
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletiontreatment2completed
NCT01453062
Phase IV Observational Study in Chronic Lymphocytic LeukemiaNot AvailableNot Availablecompleted
NCT00748189
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemiatreatment3terminated
NCT01563055
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignanciestreatment1 / 2not_yet_recruiting
NCT01832597
Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative DisordersNo drug interventionsNot AvailableNot Availablecompleted
NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesNo drug interventionstreatment1recruiting
NCT00349349
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumabtreatment2completed
NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological CancersNo drug interventionstreatment2completed
NCT00751296
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT01520922
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)treatment2completed
NCT01077622
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemiatreatment2completed
NCT00457782
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaNo drug interventionstreatment1completed
NCT00504491
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemiatreatment2withdrawn
NCT01659255
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLtreatment1completed
NCT03294980
Chronic Lymphoid Leukaemia Observatory in Finistere Area, FranceNo drug interventionsNot AvailableNot Availablerecruiting
NCT03524235
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLtreatment1active_not_recruiting
NCT04512105
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemiatreatment1active_not_recruiting
NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)treatment3recruiting
NCT06073821
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)treatment3recruiting
NCT05517265
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)Not AvailableNot Availablerecruiting
NCT06506643
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasmstreatment1 / 2recruiting
NCT01168921
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01675102
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)No drug interventionsNot AvailableNot Availablecompleted
NCT05246345
Venetoclax Resistance Landscape in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablerecruiting
NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLtreatment1 / 2completed
NCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorderstreatment2completed
NCT03283137
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLtreatment1active_not_recruiting
NCT01199575
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT00021749
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic LeukemiaNo drug interventionstreatment1 / 2completed
NCT04016636
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT01465334
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLLtreatment2terminated
NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLLNo drug interventionstreatment1withdrawn
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignanciestreatment1 / 2active_not_recruiting
NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemiatreatment1terminated
NCT03868722
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatmentprevention2 / 3recruiting
NCT05316831
Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic LeukemiaNo drug interventionsprevention4completed
NCT04746092
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19No drug interventionsNot AvailableNot Availableunknown_status
NCT06557304
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in ChinaNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT02377869
Heavy Light Chain in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT03919214
Hypertension Management in Cancer PatientsNo drug interventionssupportive_careNot Availableterminated
NCT00628238
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)treatment2unknown_status
NCT01191190
Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01703364
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLLtreatment1 / 2completed
NCT06489184
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in ChinaNot AvailableNot Availablenot_yet_recruiting
NCT03231579
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT05869279
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic LeukemiaNo drug interventionstreatment1 / 2recruiting
NCT00792077
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatiguetreatment2completed
NCT01862445
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL PatientsNo drug interventionsNot AvailableNot Availableunknown_status
NCT05610228
Study of the Metabolism in the Lymphatic Niche of CLLNo drug interventionsNot AvailableNot Availablerecruiting
NCT02046928
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment2terminated
NCT04640909
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsNo drug interventionsbasic_scienceNot Availablerecruiting
NCT03572634
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLtreatment1 / 2terminated
NCT01397916
Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)No drug interventionsNot AvailableNot Availablecompleted
NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relativestreatment2terminated
NCT02229422
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)treatment1 / 2active_not_recruiting
NCT04923048
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.No drug interventionstreatment1 / 2recruiting
NCT02828774
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT00535873
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Oldertreatment2completed
NCT04694560
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaNo drug interventionsNot AvailableNot Availablewithdrawn
NCT04639362
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.treatment2active_not_recruiting
NCT00185692
Allogeneic Transplantation From Related Haploidentical Donorstreatment2completed
NCT02863692
Registry of the German CLL Study GroupNo drug interventionsNot AvailableNot Availablerecruiting
NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumorstreatment1 / 2active_not_recruiting
NCT03113695
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrometreatment1completed
NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorderstreatment2completed
NCT05209308
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLtreatment2withdrawn
NCT05645172
Retention Rate of Acalabrutinib in a Non-interventional SettingNo drug interventionsNot AvailableNot Availablerecruiting
NCT02273856
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)No drug interventionsNot AvailableNot Availableterminated
NCT02920697
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphomatreatment1completed
NCT01279252
CLL Empirical Antibiotic Regimentreatment2completed
NCT00923507
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)No drug interventionsNot AvailableNot Availablerecruiting
NCT01087333
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentNo drug interventionsNot AvailableNot Availablerecruiting
NCT04895436
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)treatment2recruiting
NCT04285567
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutationtreatment3active_not_recruiting
NCT04419519
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclaxtreatment2recruiting
NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsNo drug interventionsNot AvailableNot Availablerecruiting
NCT05557695
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United KingdomNot AvailableNot Availablerecruiting
NCT05724121
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxNo drug interventionsNot AvailableNot Availablerecruiting
NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNo drug interventionstreatment1recruiting
NCT00919321
The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLLNo drug interventionsprevention4completed
NCT00458679
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cellstreatment1completed
NCT01125787
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumabtreatment2terminated
NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TNo drug interventionsother1enrolling_by_invitation
NCT00840853
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRATtreatment1active_not_recruiting
NCT05144347
Study of XL114 in Subjects With Non-Hodgkin's LymphomaNo drug interventionstreatment1terminated
NCT01768845
Unrelated Umbilical Cord Blood (UBC)TransplantationNo drug interventionstreatmentNot Availablecompleted
NCT03588598
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesNo drug interventionstreatment1unknown_status
NCT01885897
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTtreatment1 / 2completed
NCT03824483
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)treatment2recruiting
NCT04655261
Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableterminated
NCT03580928
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLtreatment2active_not_recruiting
NCT02136511
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic LeukemiaNot AvailableNot Availableapproved_for_marketing
NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesNo drug interventionstreatment1 / 2recruiting
NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2recruiting
NCT03406156
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapytreatment3completed
NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLtreatment1recruiting
NCT01463852
A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)basic_science0terminated
NCT01532700
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01754870
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)treatment2withdrawn
NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersNo drug interventionstreatmentNot Availablerecruiting
NCT01517035
Improving Blood Stem Cell Collection and Transplant ProceduresNo drug interventionstreatment1 / 2completed
NCT01203930
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLtreatment2terminated
NCT03771157
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitorssupportive_care0completed
NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesNo drug interventionstreatment1 / 2recruiting
NCT01976520
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment1unknown_status
NCT02980731
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).treatment3completed
NCT00439231
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2completed
NCT03085173
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic MalignanciesNo drug interventionstreatment1active_not_recruiting
NCT01419691
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT02086591
A Phase II Study of Doxycycline in Relapsed NHLtreatment2terminated
NCT03788291
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairstreatment2terminated
NCT02793544
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamidetreatment2completed
NCT04215367
Dietary Intervention With High Phenolic EVOO in CLLNo drug interventionstreatmentNot Availablecompleted
NCT04447768
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)treatment2active_not_recruiting
NCT03659669
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeNo drug interventionsNot AvailableNot Availablesuspended
NCT00640523
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT04767308
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignanciestreatment0unknown_status
NCT01527838
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitNo drug interventionstreatment1completed
NCT00694590
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1completed
NCT01050764
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellstreatment1 / 2terminated
NCT04209621
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2terminated
NCT02582879
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT01500733
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT01466153
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT02371577
Evaluation of the Immune Restoration Potential Of Lenalidomidetreatment2withdrawn
NCT00664677
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemiatreatment1terminated
NCT01131247
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumabtreatment2withdrawn
NCT00889798
Tumor Registry of Lymphatic NeoplasiaNo drug interventionsNot AvailableNot Availablecompleted
NCT00467961
Stem Cell Transplantation for Patients With Cancers of the BloodNo drug interventionstreatment2completed
NCT02226861
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantationprevention1completed
NCT01580228
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)treatment3completed
NCT00710528
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignanciestreatment1completed
NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomatreatment1 / 2completed
NCT01145209
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLLtreatment2completed
NCT04198415
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)No drug interventionsNot AvailableNot Availablecompleted
NCT04685915
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLtreatment2withdrawn
NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaNo drug interventionstreatment1 / 2terminated
NCT02580552
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLtreatment1completed
NCT04758975
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)treatment2recruiting
NCT00614042
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphomatreatment1completed
NCT01117142
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersNo drug interventionsNot AvailableNot Availablecompleted
NCT05105841
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment2active_not_recruiting
NCT04178317
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical PracticeNo drug interventionsNot AvailableNot Availablerecruiting
NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNo drug interventionstreatment1recruiting
NCT01241786
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLLtreatment2terminated
NCT01723839
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomidetreatment2completed
NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNo drug interventionstreatment1recruiting
NCT05168930
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)treatment2recruiting
NCT03873857
A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian FederationNot AvailableNot Availablecompleted
NCT05708326
A Case Crossover Study of Intermittent Fasting in CLL/SLLNo drug interventionspreventionNot Availablecompleted
NCT00230282
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemiatreatment2completed
NCT03702231
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)basic_science2completed
NCT02265731
Study Evaluating Venetoclax in Subjects With Hematological Malignanciestreatment1 / 2completed
NCT03400176
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinibtreatment1terminated
NCT03123029
Expanded Access to VenetoclaxNot AvailableNot Availableavailable
NCT02269592
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeNo drug interventionsNot AvailableNot Availablerecruiting
NCT03342144
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignanciestreatment1not_yet_recruiting
NCT02553304
Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT01413568
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesNo drug interventionstreatment1 / 2completed
NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesNo drug interventionstreatment1completed
NCT01188681
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT02538614
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemiatreatment1terminated
NCT00185523
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)No drug interventionsNot AvailableNot Availableterminated
NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphomatreatment1terminated
NCT00039676
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasestreatmentNot Availablerecruiting
NCT02048813
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment3active_not_recruiting
NCT02157324
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemiatreatment1active_not_recruiting
NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignanciestreatment1active_not_recruiting
NCT02477696
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)treatment3active_not_recruiting
NCT02500407
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)treatment1 / 2active_not_recruiting
NCT02846623
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrometreatment2recruiting
NCT03128879
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLtreatment2recruiting
NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T CellsNo drug interventionsNot AvailableNot Availablerecruiting
NCT03467867
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLtreatment2active_not_recruiting
NCT03737981
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemiatreatment3active_not_recruiting
NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantationsupportive_care2active_not_recruiting
NCT04240704
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHLNo drug interventionstreatment1terminated
NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Studytreatment3recruiting
NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumabtreatment1 / 2completed
NCT04624633
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLtreatment2active_not_recruiting
NCT04666038
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT04679012
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformationtreatment2recruiting
NCT04722172
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLtreatment2active_not_recruiting
NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment1recruiting
NCT05405309
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemiatreatment1 / 2terminated
NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaNo drug interventionstreatment1recruiting
NCT06125795
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainNo drug interventionsNot AvailableNot Availablerecruiting
NCT06291220
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment1recruiting
NCT06428019
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)treatment3recruiting
NCT06520098
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment2not_yet_recruiting
NCT06524375
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.treatment2recruiting
NCT06654206
Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia PatientsNo drug interventionstreatment0not_yet_recruiting
NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)treatment3enrolling_by_invitation
NCT03701282
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemiatreatment3active_not_recruiting
NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemiatreatment3completed
NCT04028531
Understanding Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablerecruiting
NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomastreatment1 / 2terminated
NCT04502030
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)prevention3active_not_recruiting
NCT04785989
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)No drug interventionsNot AvailableNot Availablerecruiting
NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNo drug interventionstreatment1 / 2recruiting
NCT05140369
CLL Therapy Approaches in RussiaNo drug interventionsNot AvailableNot Availablerecruiting
NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNo drug interventionsNot AvailableNot Availablerecruiting
NCT05624554
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)treatment3recruiting
NCT05878184
Study Evaluating SC291 in Subjects with R/r B-cell Malignancies (ARDENT)treatment1recruiting
NCT05879133
HEALTH4CLL2: a Randomized Waitlist Control Trial of Behavioral Interventions in Patients with Chronic Lymphocytic LeukemiaNo drug interventionssupportive_careNot Availablerecruiting
NCT06001385
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxistreatment2recruiting
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)treatment3recruiting
NCT06544785
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2recruiting
NCT06644183
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)treatment1 / 2not_yet_recruiting
NCT02135133
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLtreatment2completed
NCT04008706
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patientstreatment3active_not_recruiting
NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplanttreatment2recruiting
NCT05317936
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclaxtreatment2active_not_recruiting
NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)treatment2recruiting
NCT05521178
Cardiotoxicities in Patients Receiving BTKiNo drug interventionsNot AvailableNot Availablewithdrawn
NCT06170671
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in RomaniaNo drug interventionsNot AvailableNot Availablerecruiting
NCT06637501
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemiatreatment2not_yet_recruiting
NCT01496976
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLtreatment2active_not_recruiting
NCT02553447
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D DeficiencyNo drug interventionstreatmentNot Availableactive_not_recruiting
NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLtreatment1 / 2recruiting
NCT04657224
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaNo drug interventionstreatment1active_not_recruiting
NCT05512390
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment1recruiting
NCT05618028
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsNo drug interventionstreatment1recruiting
NCT06636175
64Cu-LLP2A for Imaging Hematologic MalignanciesNo drug interventionsdiagnostic0not_yet_recruiting
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLtreatment1 / 2active_not_recruiting
NCT03836261
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLtreatment3active_not_recruiting
NCT03986034
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)basic_science2recruiting
NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular LymphomaNot AvailableNot Availablerecruiting
NCT05797233
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignanciestreatment1active_not_recruiting
NCT04684563
huCART19-IL18 in CD19+ CancersNo drug interventionstreatment1recruiting
NCT04732845
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignanciestreatment1recruiting
NCT04746950
ALICIA (Acalabrutinib in CLL Therapy)No drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT05336812
Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemiatreatment2recruiting
NCT05388006
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2recruiting
NCT05544019
Study of SGR-1505 in Mature B-Cell NeoplasmsNo drug interventionstreatment1recruiting
NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplanttreatment2recruiting
NCT06205498
Acalabrutinib Real World Italian obSErvational Study -ARISENot AvailableNot Availablerecruiting
NCT06548152
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2not_yet_recruiting
NCT00159003
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in IsraelNo drug interventionsNot AvailableNot Availablecompleted
NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence)No drug interventionssupportive_careNot Availablecompleted
NCT02656303
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304treatment2terminated
NCT00525603
CFAR Study in Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT03708003
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLtreatment2active_not_recruiting
NCT01292603
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemiatreatment1completed
NCT01243190
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment2completed
NCT03671590
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignanciestreatment1terminated
NCT02891590
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasNo drug interventionstreatment1completed
NCT05694364
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignanciestreatment1recruiting
NCT01109264
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemiatreatment2completed
NCT00600964
A Phase I/II Study of GX15-070MS in Untreated CLLtreatment1completed
NCT03980002
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLtreatment2recruiting
NCT00771602
Alemtuzumab + Rituximab Consolidation in CLLtreatment2terminated
NCT03153202
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)treatment1 / 2recruiting
NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantationtreatment2recruiting
NCT02080884
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT00898079
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT05555979
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United KingdomNo drug interventionsNot AvailableNot Availablecompleted
NCT04159779
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in GreeceNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)treatment1terminated
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT01905943
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemiatreatment3completed
NCT02194387
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family MembersNo drug interventionspreventionNot Availableactive_not_recruiting
NCT01722487
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLLtreatment3completed
NCT00990587
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancytreatment1completed
NCT00081887
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemiatreatment1terminated
NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLtreatment3active_not_recruiting
NCT05212233
Financial Difficulty in Patients With Blood CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT05844033
Biomarker for Infection Risk in CLL and MMNo drug interventionsNot AvailableNot Availablerecruiting
NCT00709033
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLLNo drug interventionstreatment1active_not_recruiting
NCT00464633
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT04545333
The clonoSEQ® Watch RegistryNo drug interventionsNot AvailableNot Availableterminated
NCT06364033
Biological and Clinical Efficacy of Shingrix in Patients With CLLNo drug interventionsbasic_scienceNot Availablenot_yet_recruiting
NCT00275054
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemiatreatment3completed
NCT01627054
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic LeukemiaNo drug interventionstreatment2completed
NCT03379051
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLtreatment1 / 2terminated
NCT02427451
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemiatreatment1 / 2active_not_recruiting
NCT04595851
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer MedicationsNo drug interventionshealth_services_researchNot Availableterminated
NCT00090051
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patientstreatment3completed
NCT03059251
Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in ArgentinaNot AvailableNot Availablecompleted
NCT01087151
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT02231853
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral InfectionsNo drug interventionsprevention1terminated
NCT05702853
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLtreatment1 / 2recruiting
NCT01557777
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)basic_science2completed
NCT05999877
PICAROS - Acalabrutinib RWE on 1L CLL in SpainNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT03765177
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesNo drug interventionstreatment1 / 2recruiting
NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignanciestreatment1completed
NCT00829647
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemiatreatment1 / 2withdrawn
NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancerstreatment1 / 2terminated
NCT04790045
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimenstreatment4not_yet_recruiting
NCT00916045
Pilot Study of Unrelated Cord Blood Transplantationtreatment2terminated
NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignanciestreatment1withdrawn
NCT02981745
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaNo drug interventionstreatment1 / 2unknown_status
NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphomatreatment1active_not_recruiting
NCT02491398
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaNot AvailableNot Availablecompleted
NCT03615105
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donorstreatment2terminated
NCT01414205
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)treatment2completed
NCT01486797
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT05950997
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLtreatmentNot Availablerecruiting
NCT00779883
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)treatment1completed
NCT01500083
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemiatreatment3completed
NCT00038883
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciestreatmentNot Availableterminated
NCT04167683
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantNo drug interventionsNot AvailableNot Availablerecruiting
NCT01271283
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemiatreatment2withdrawn
NCT02514083
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLLtreatment2active_not_recruiting
NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Matchtreatment2terminated
NCT00102661
Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgerytreatment1completed
NCT01013961
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemiatreatment2terminated
NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplanttreatment2completed
NCT04908228
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLLtreatment2recruiting
NCT00743028
Assess the Oral Bioavailability of New ABT-263 Formulationstreatment1completed
NCT04844528
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)treatment2recruiting
NCT00100711
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2terminated
NCT01161511
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemiatreatment1completed
NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantationsupportive_care1terminated
NCT01459211
Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)treatment2completed
NCT03609593
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemiatreatment2active_not_recruiting
NCT00758693
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)treatment2withdrawn
NCT01868893
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemiatreatment2completed
NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment3recruiting
NCT01181271
Tandem Auto-Allo Transplant for Lymphomatreatment2completed
NCT00676871
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)treatment1 / 2withdrawn
NCT02005471
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment3completed
NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductNo drug interventionsNot AvailableNot Availableterminated
NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNo drug interventionstreatment1recruiting
NCT02222688
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment1completed
NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and RecoveryNo drug interventionsNot AvailableNot Availablecompleted
NCT01098188
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemiatreatment1completed
NCT01585688
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLNo drug interventionstreatment1 / 2terminated
NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplanttreatment1 / 2recruiting
NCT00783588
A Phase I Extension Trial of Repeated Infusions of ISF35treatment1completed
NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Diseasetreatment2active_not_recruiting
NCT00290407
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)treatment2terminated
NCT04771507
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)treatment1 / 2recruiting
NCT00276809
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemiatreatment2completed
NCT01567709
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphomatreatment1completed
NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT ScansNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35treatment2terminated
NCT03316209
Identification of Occupational Exposures in Acute Hematologic MalignancyNo drug interventionsNot AvailableNot Availablecompleted
NCT01076556
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1terminated
NCT01123356
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximabtreatment2completed
NCT03207256
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trialstreatment2terminated
NCT01510756
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLtreatment1completed
NCT04688385
Personalized Multi-peptide Vaccination in CLL PatientsNo drug interventionstreatment1active_not_recruiting
NCT02057185
Occupational Status and Hematological DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumorstreatment1 / 2terminated
NCT01149915
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemiastreatment1completed
NCT01081015
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease RegistryNo drug interventionsNot AvailableNot Availablecompleted
NCT02049515
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07treatment3completed
NCT00962715
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemiatreatment1 / 2withdrawn
NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)treatment2withdrawn
NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropeniatreatment1completed
NCT04867915
Study on the Diagnosis and Management of CLL in Italy by GIMEMANo drug interventionsNot AvailableNot Availablerecruiting
NCT03374137
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaNot AvailableNot Availablecompleted
NCT03076437
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesNo drug interventionstreatment1 / 2completed
NCT00496132
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaNo drug interventionstreatment1 / 2terminated
NCT01113632
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT01699152
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1completed
NCT06536452
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control SubjectsNo drug interventionsNot AvailableNot Availablerecruiting
NCT02294552
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCTtreatment2completed
NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplantsupportive_care1active_not_recruiting
NCT04189952
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphomatreatment2terminated
NCT04887259
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AMLtreatment1 / 2active_not_recruiting
NCT03197259
Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National StudyNo drug interventionsNot AvailableNot Availablerecruiting
NCT00632359
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Diseasetreatment2completed
NCT04716075
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)treatment2active_not_recruiting
NCT04796675
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignanciestreatment1unknown_status
NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancertreatment2completed
NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT00562770
Oral Valganciclovir Versus Valacyclovirtreatment2completed
NCT00446342
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignanciestreatment1completed
NCT03943342
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistancetreatment2withdrawn
NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseasestreatment2completed
NCT02242942
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemiatreatment3active_not_recruiting
NCT00864942
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)treatment1completed
NCT02381899
Observational Study in CLL Patients Receiving BRNot AvailableNot Availablecompleted
NCT01610999
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantationtreatment1terminated
NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantationtreatment2active_not_recruiting
NCT04862806
Safety, Efficacy of BNT162b2 mRNA Vaccine in CLLNo drug interventionsdiagnosticNot Availableunknown_status
NCT00233506
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treatedtreatment1completed
NCT01369849
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1 / 2completed
NCT01397149
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)treatment1 / 2terminated
NCT03150849
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)treatment1 / 2active_not_recruiting
NCT00868413
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment1completed
NCT00193518
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2completed
NCT02296918
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLtreatment1active_not_recruiting
NCT00028418
Clofarabine in Chronic Lymphocytic Leukemiatreatment1completed
NCT00038818
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationNo drug interventionstreatmentNot Availableterminated
NCT01892618
Pneumococcal Vaccine in Untreated CLL Patientstreatment3completed
NCT02970318
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLtreatment3active_not_recruiting
NCT00448019
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT05677919
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemiatreatment2recruiting
NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorderstreatment1terminated
NCT00337519
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemiatreatment2unknown_status
NCT01013441
CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic LeukemiaNo drug interventionstreatment1completed
NCT04938141
MEOI and HRQoL in CLL Patients Treated With BTKisNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT01272817
Nonmyeloablative Allogeneic TransplantNo drug interventionstreatmentNot Availablecompleted
NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)treatment1completed
NCT02983617
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT03516617
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2recruiting
NCT03514017
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemiatreatment2terminated
NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationNo drug interventionstreatment1completed
NCT01460134
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancerstreatment1completed
NCT02784834
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLLtreatment1terminated
NCT03939234
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.No drug interventionstreatment2completed
NCT02396134
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_care2active_not_recruiting
NCT00378534
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplantstreatment2completed
NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)treatment2unknown_status
NCT00060424
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemiatreatment2completed
NCT01682616
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1completed
NCT01497496
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment2completed
NCT06521996
M-CHOP in Richter´s Syndrometreatment2recruiting
NCT01351896
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT05360758
Ibrutinib Adapted to Response in Patients With CLLNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT00104858
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignanciestreatment1 / 2completed
NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803treatment1completed
NCT03415035
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT01351935
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemiatreatment1completed
NCT02661035
Allo HSCT Using RIC for Hematological Diseasestreatment2completed
NCT02345863
Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patientstreatment2completed
NCT02968563
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01408563
Reduced Intensity Double Umbilical Cord Blood Transplantationtreatment2completed
NCT01364363
Unrelated Donor Stem Cell TransplantationNo drug interventionstreatmentNot Availablecompleted
NCT01066663
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment1 / 2completed
NCT01110863
Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging SubjectsNo drug interventionsNot AvailableNot Availablecompleted
NCT01178086
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)Not AvailableNot Availablecompleted
NCT00001586
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysistreatment2completed
NCT02535286
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformationtreatment1completed
NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenNo drug interventionsNot AvailableNot Availablerecruiting
NCT05718986
Familial B-cell Lymphoproliferative DisordersNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancertreatment2active_not_recruiting
NCT00934986
Natural Killer Cells Function in Patients With Chronic Lymphocytic LeukemiaNo drug interventionsbasic_scienceNot Availablecompleted
NCT01082939
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01849939
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic LeukemiaNo drug interventionstreatment2unknown_status
NCT04501939
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclaxtreatment2active_not_recruiting
NCT03056339
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignanciestreatment1 / 2completed
NCT04852822
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNo drug interventionsNot AvailableNot Availableterminated
NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancertreatment1recruiting
NCT04560322
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLtreatment2recruiting
NCT01832922
BR in Patients With CLL With Comorbidities and/or Renal Dysfunctiontreatment1completed
NCT01353625
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.treatment1completed
NCT06151730
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyNo drug interventionsNot AvailableNot Availablerecruiting
NCT00176930
Stem Cell Transplant for Hematological MalignancytreatmentNot Availableterminated
NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNo drug interventionstreatment1recruiting
NCT00319930
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLLtreatment1terminated
NCT01465230
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemiatreatment2terminated
NCT00735930
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1completed
NCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trialtreatment3active_not_recruiting
NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)treatment1active_not_recruiting
NCT01120457
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancerstreatment1completed
NCT00860457
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT04370457
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic MalignanciesNo drug interventionssupportive_careNot Availableunknown_status
NCT00036257
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic LeukemiaNo drug interventionstreatment1completed
NCT02156726
Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite ProjectNot AvailableNot Availableunknown_status
NCT01300026
AMG 319 Lymphoid Malignancy FIHNo drug interventionstreatment1completed
NCT01328626
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomatreatment1completed
NCT00391066
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignanciestreatment1completed
NCT05417165
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemiaprevention2recruiting
NCT04691765
Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patientstreatment1unknown_status
NCT03971565
Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT00143065
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT06250465
AGMT Austrian CLL (Chronic Lymphocytic Leukemia) RegistryNo drug interventionsNot AvailableNot Availablerecruiting
NCT03454165
A Study of BNC105P Combined With Ibrutinibtreatment1completed
NCT05154474
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyNo drug interventionsNot AvailableNot Availableunknown_status
NCT06367374
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLtreatment2not_yet_recruiting
NCT04282174
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignanciestreatment2withdrawn
NCT00738374
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.treatment2completed
NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersNo drug interventionstreatment2recruiting
NCT01346020
Genomic Analysis of Patients With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT05556720
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trialtreatment3recruiting
NCT03893682
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomastreatment1active_not_recruiting
NCT01045382
MSC and HSC Coinfusion in Mismatched MinitransplantsNo drug interventionstreatment2terminated
NCT06379282
Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic LeukaemiaNo drug interventionssupportive_careNot Availablerecruiting
NCT00262782
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemiatreatment3completed
NCT00201682
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1 / 2completed
NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignanciestreatment2completed
NCT00038831
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDStreatment1 / 2completed
NCT00899431
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT00889031
Protocol to Obtain Blood Samples for Leukemia ResearchNo drug interventionsNot AvailableNot Availablecompleted
NCT00792831
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemiatreatment2terminated
NCT01853631
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)No drug interventionstreatment1recruiting
NCT00083473
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemiatreatment2terminated
NCT03328273
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment1active_not_recruiting
NCT00001873
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood CancersNo drug interventionstreatment2completed
NCT03191773
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell MalignanciesNo drug interventionstreatment1 / 2unknown_status
NCT00431873
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemiatreatment2completed
NCT03847727
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT05739227
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesNo drug interventionstreatment0recruiting
NCT02860676
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961treatment1completed
NCT00872976
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemiatreatment1withdrawn
NCT01125176
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLLtreatment2completed
NCT01556776
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapytreatment3completed
NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLtreatment1 / 2unknown_status
NCT05959694
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .No drug interventionstreatment1 / 2recruiting
NCT02158091
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLtreatment1 / 2active_not_recruiting
NCT01649791
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic LeukemiatreatmentNot Availableterminated
NCT00586391
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLtreatment1active_not_recruiting
NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioningtreatment2completed
NCT01185262
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemiatreatment1completed
NCT00810680
Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)treatmentNot Availableunknown_status
NCT02340780
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemiatreatment2completed
NCT01998880
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)treatment3completed
NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)treatment1completed
NCT00286780
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT00393380
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donorprevention2terminated
NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT02337829
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLtreatment2active_not_recruiting
NCT04629729
FT819 in Subjects With B-cell Malignanciestreatment1active_not_recruiting
NCT00532129
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.treatment2completed
NCT04419389
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)treatment1 / 2terminated
NCT00274989
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemiatreatment2completed
NCT00073489
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaNo drug interventionstreatment1 / 2unknown_status
NCT01841489
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 PharmacokineticsNo drug interventionstreatment1completed
NCT00281892
Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemiatreatment3completed
NCT05371392
Polymorphism of ITGA4 Gene in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT03495492
Chronic Lymphocytic Leukemia Responds to Dermal ChelationNo drug interventionstreatmentNot Availableunknown_status
NCT05020392
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphomatreatment3recruiting
NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTtreatment2completed
NCT04774744
Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaNo drug interventionssupportive_careNot Availablecompleted
NCT00593944
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment1completed
NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplantsupportive_care2withdrawn
NCT01255644
Antiviral Treatment of Chronic Lymphocytic Leukemiatreatment4completed
NCT03892044
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphomatreatment1completed
NCT01399840
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignanciestreatment1completed
NCT04155840
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2terminated
NCT01558167
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT05145101
Pneumococcal Vaccination in Patients With Chronic Lymphocytic LeukaemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantationtreatment2completed
NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignanciestreatment1 / 2withdrawn
NCT02533401
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT00381004
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemiatreatment2completed
NCT04814004
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell TumorsNo drug interventionstreatment1unknown_status
NCT01671904
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT03676504
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CARtreatment1 / 2recruiting
NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.No drug interventionstreatment1recruiting
NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT05718869
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Studytreatment2recruiting
NCT06475469
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious RiskNo drug interventionsscreeningNot Availablerecruiting
NCT01539512
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)treatment3completed
NCT00535912
Phase III Study Treatment of CLL B and CNo drug interventionstreatment3completed
NCT01352312
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphomatreatment1terminated
NCT05478512
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLLNo drug interventionstreatment2recruiting
NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplanttreatment3completed
NCT01056510
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)treatment4completed
NCT01271010
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Statustreatment4terminated
NCT00254410
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Yearstreatment2completed
NCT02053610
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)treatment3completed
NCT02475681
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLtreatment3active_not_recruiting
NCT04059081
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessmenttreatment2unknown_status
NCT04160195
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphomatreatment1terminated
NCT00262795
Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemiatreatment3completed
NCT00466895
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.treatment1completed
NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLtreatment1 / 2completed
NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancytreatment1terminated
NCT01090414
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Studytreatment1 / 2terminated
NCT00131014
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesNo drug interventionsNot AvailableNot Availablerecruiting
NCT03207555
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT05672355
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemiaprevention2recruiting
NCT00183950
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapytreatment1 / 2terminated
NCT00946023
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximabtreatment2terminated
NCT00036023
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignanciestreatment2completed
NCT06084923
Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease ProgressionNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT04704323
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic LeukemiaNo drug interventionstreatment1recruiting
NCT03534323
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RStreatment1 / 2active_not_recruiting
NCT03447808
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemiatreatment1active_not_recruiting
NCT00108108
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapytreatment1terminated
NCT04504708
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesNo drug interventionstreatment1 / 2terminated
NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHDtreatmentNot Availableterminated
NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemiatreatment2recruiting
NCT02611908
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.treatment1withdrawn
NCT00836043
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic LeukemiaNot AvailableNot Availableterminated
NCT04282343
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic CancerNo drug interventionshealth_services_researchNot Availablecompleted
NCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemiatreatment1 / 2active_not_recruiting
NCT00759603
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemiatreatment2completed
NCT00285103
SPC2996 in Chronic Lymphocytic Leukaemiatreatment1 / 2completed
NCT00186303
Transplantation for Patients With Chronic Lymphocytic LeukemiaNo drug interventionstreatmentNot Availablecompleted
NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLtreatment1 / 2recruiting
NCT00714103
8-Chloro-Adenosine in Chronic Lymphocytic Leukemiatreatment1completed
NCT00086203
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT02401503
Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)treatment2active_not_recruiting
NCT01611090
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment3completed
NCT03310190
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeNo drug interventionsNot AvailableNot Availablecompleted
NCT02371590
Lenalidomide and Obinutuzumab for Previously Untreated CLLtreatment2withdrawn
NCT02742090
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapytreatment2terminated
NCT01659021
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemiatreatment3terminated
NCT04149821
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapytreatment2terminated
NCT01290302
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemiatreatment1completed
NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumorstreatment1 / 2completed
NCT02924402
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignanciestreatment1active_not_recruiting
NCT00749502
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)treatment1completed
NCT02131584
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemiasupportive_care2active_not_recruiting
NCT05287984
Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLtreatment2not_yet_recruiting
NCT04978779
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrometreatment1terminated
NCT02507479
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignanciestreatment2unknown_status
NCT01392079
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabinetreatment2completed
NCT01173679
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLtreatment2terminated
NCT02320487
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01973387
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphomatreatment3completed
NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplantsupportive_care2active_not_recruiting
NCT00428233
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine GenerationNo drug interventionstreatment1completed
NCT02640833
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitortreatment1withdrawn
NCT03870633
Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple MyelomaNo drug interventionsNot AvailableNot Availablecompleted
NCT00974233
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLtreatment2completed
NCT05183854
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trialtreatment2recruiting
NCT04505254
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemiatreatment2recruiting
NCT00438854
Dasatinib in Relapsed Chronic Lymphocytic Leukemiatreatment2completed
NCT04094051
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeNot AvailableNot Availableunknown_status
NCT05971251
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemiatreatment1recruiting
NCT01455051
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantationtreatment2completed
NCT02950051
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutationtreatment3completed
NCT00899353
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)No drug interventionstreatment2terminated
NCT01644253
Phase 1b Safety and Efficacy Study of TRU-016treatment1terminated
NCT01600053
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemiatreatment2terminated
NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyNo drug interventionssupportive_careNot Availableactive_not_recruiting
NCT01659047
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemiatreatment2withdrawn
NCT00587847
Campath Maintenance in Chronic Lymphocytic LeukemiatreatmentNot Availableterminated
NCT01300247
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)treatment1completed
NCT00931645
Autologous Stem Cell Transplantation in Chronic Lymphocytic LeukemiaNo drug interventionstreatment3completed
NCT03633045
Observational Study of Ibrutinib Use in CLLNo drug interventionsNot AvailableNot Availableunknown_status
NCT01350245
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donortreatment2completed
NCT01848145
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemiatreatment2completed
NCT01527045
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignanciesprevention2completed
NCT02242045
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT04660045
Early Intervention With Acalabrutinib in Patients With High Risk CLLtreatment2withdrawn
NCT00143845
Study of Low-Intensity Conditioning for Allogeneic Stem Cell TransplantNo drug interventionstreatment2completed
NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesNo drug interventionstreatment2terminated
NCT00759798
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT04016805
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclaxtreatment2terminated
NCT02756897
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemiatreatment2active_not_recruiting
NCT02316197
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemiatreatment1completed
NCT02481297
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patientstreatment2completed
NCT02320383
CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patientstreatment2unknown_status
NCT00281983
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemiatreatment1 / 2completed
NCT02910583
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)treatment2completed
NCT02819583
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaNo drug interventionstreatment1 / 2unknown_status
NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafortreatment2completed
NCT00558961
Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patientstreatment1 / 2terminated
NCT01010061
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)treatment3completed
NCT02013128
Ublituximab + Ibrutinib in Select B-cell Malignanciestreatment1 / 2completed
NCT00772811
Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myelomatreatment2completed
NCT02756611
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)treatment3completed
NCT06396611
Exercise as Intervention in Chronic Lymphocytic LeukemiaNo drug interventionstreatmentNot Availablerecruiting
NCT02612311
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemiatreatment3terminated
NCT02717611
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapytreatment2active_not_recruiting
NCT01629511
Allogeneic Stem Cell Transplant for CLLtreatment1 / 2terminated
NCT02042911
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic LeukemiaNo drug interventionstreatment2completed
NCT04282811
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in ItalyNot AvailableNot Availablerecruiting
NCT03422393
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinibtreatment1active_not_recruiting
NCT01224093
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)Not AvailableNot Availablecompleted
NCT01295593
Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)treatment1 / 2unknown_status
NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemiatreatment1terminated
NCT02801578
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)treatment2 / 3completed
NCT00868478
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)treatment1 / 2unknown_status
NCT00413478
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemiatreatment2terminated
NCT01980888
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemiatreatment3terminated
NCT00046488
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)Not Available1completed
NCT00949988
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemiatreatment1 / 2terminated
NCT04904588
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamidetreatment2recruiting
NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLtreatment1terminated
NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donorstreatment2completed
NCT03088709
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamideprevention2terminated
NCT01787409
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyNo drug interventionstreatmentNot Availablerecruiting
NCT02629809
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemiatreatment2active_not_recruiting
NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaNo drug interventionstreatment2recruiting
NCT02301156
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)treatment3completed
NCT00058656
Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) PatientsNo drug interventionstreatment1 / 2completed
NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignanciestreatment1terminated
NCT00109356
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LeukemiaNo drug interventionstreatment1 / 2unknown_status
NCT05928156
Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCTNo drug interventionssupportive_careNot Availablecompleted
NCT03370185
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphomatreatment2withdrawn
NCT02006485
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignanciestreatment1completed
NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Preventionsupportive_care3completed
NCT01051115
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Diseasetreatment2unknown_status
NCT00038415
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic ApproachNo drug interventionstreatment1 / 2terminated
NCT01395615
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic LeukaemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT00880815
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplanttreatment1completed
NCT01534715
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemiatreatment1completed
NCT02530515
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic LeukemiaNo drug interventionstreatment2completed
NCT00275015
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemiatreatment2completed
NCT00727415
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapytreatment1 / 2completed
NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)prevention2completed
NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignanciestreatment1completed
NCT00001637
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older AdultsNo drug interventionstreatment2completed
NCT01069432
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablewithdrawn
NCT01423032
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)treatment2 / 3completed
NCT01445132
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell TransplantationNo drug interventionstreatment1completed
NCT00100152
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)treatment1terminated
NCT04950452
Exercise Training to Promote Resilience to Chronic Lymphocytic LeukemiaNo drug interventionshealth_services_researchNot Availablecompleted
NCT02100852
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT00330252
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLtreatment1completed
NCT00145652
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.treatment3completed
NCT04663100
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy AdherenceNo drug interventionshealth_services_researchNot Availablerecruiting
NCT04464200
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersNo drug interventionstreatment1active_not_recruiting
NCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic MalignanciesNo drug interventionstreatment2terminated
NCT04980859
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 MutationNo drug interventionstreatment3not_yet_recruiting
NCT00267059
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01871675
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignanciestreatment1completed
NCT01251575
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplanttreatment2completed
NCT01980875
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemiatreatment3terminated
NCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignanciestreatment2terminated
NCT00569842
Investigation of the Cylex® ImmuKnow® AssayNo drug interventionsNot AvailableNot Availablecompleted
NCT00270049
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemiatreatment2completed
NCT00289549
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT01290549
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphomatreatment1completed
NCT03913949
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignanciestreatment1active_not_recruiting
NCT00718549
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)treatment3completed
NCT00596336
Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patientsprevention2terminated
NCT01030536
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)treatment1 / 2completed
NCT00151736
Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT02993536
Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximabNo drug interventionsNot AvailableNot Availablewithdrawn
NCT02825836
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjectstreatment1 / 2active_not_recruiting
NCT01030913
B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene ExpressionNo drug interventionsNot AvailableNot Availablecompleted
NCT06211413
Hypertension and Arrhythmias in CLL Patients Treated With BTK InhibitorsNo drug interventionsNot AvailableNot Availableenrolling_by_invitation
NCT01410513
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemiatreatment1completed
NCT02537613
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment1active_not_recruiting
NCT00131313
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.treatment4unknown_status
NCT04578613
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLtreatment3recruiting
NCT02863718
Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progressiontreatment3completed
NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic MalignanciesNo drug interventionstreatment1recruiting
NCT04163718
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT02689141
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)treatment2completed
NCT00280241
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemiatreatment2completed
NCT05410041
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell MalignanciesNo drug interventionstreatment1unknown_status
NCT01625741
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapytreatment2terminated
NCT03528941
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With IbrutinibNot AvailableNot Availablecompleted
NCT04312841
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumabtreatment2active_not_recruiting
NCT00536341
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)treatment1 / 2completed
NCT04342117
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLNot AvailableNot Availableterminated
NCT02827617
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic LeukemiaNot AvailableNot Availableactive_not_recruiting
NCT02013817
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapytreatment2completed
NCT00078234
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT01118234
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)treatment3completed
NCT02915224
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesNot AvailableNot Availablecompleted
NCT02109224
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infectiontreatment1terminated
NCT00562224
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patientstreatment1completed
NCT03436524
A Prognostic Tool for Early Stage CLLNo drug interventionsNot AvailableNot Availablecompleted
NCT00849524
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment2terminated
NCT02557516
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLtreatment1 / 2terminated
NCT02461316
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT02900716
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasNo drug interventionstreatment1completed
NCT01444716
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemiatreatment2completed
NCT00514696
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemiatreatment2completed
NCT05943496
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1recruiting
NCT00071396
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorderstreatment2completed
NCT01021358
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).treatment1completed
NCT00103558
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)treatment1 / 2completed
NCT00481858
Kinetic Biomarker for Chronic Lymphocytic Leukemia PrognosisNo drug interventionsNot AvailableNot Availablecompleted
NCT01181258
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignanciestreatment2completed
NCT03545035
Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC StudyNot AvailableNot Availablecompleted
NCT04754035
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemiatreatment2active_not_recruiting
NCT05643235
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase InhibitorsNo drug interventionsotherNot Availablerecruiting
NCT00274963
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment2completed
NCT01681563
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT01889186
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletiontreatment2completed
NCT01283386
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Statustreatment4terminated
NCT00772486
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLLtreatment1completed
NCT00499239
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)treatment1 / 2terminated
NCT00769522
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemiatreatment3completed
NCT02004522
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)treatment3completed
NCT06466122
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKitreatment2recruiting
NCT04245722
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodiestreatment1terminated
NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphomatreatment2active_not_recruiting
NCT02414022
Economic Analysis of Alliance A041202 CLL StudyNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT03492125
A Study Of The Selective PKC-β Inhibitor MS- 553treatment1 / 2terminated
NCT02292225
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)treatment1terminated
NCT03801525
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)treatment2 / 3terminated
NCT02071225
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemiatreatment2completed
NCT00038025
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignanciestreatment2completed
NCT04666025
SARS-CoV-2 Donor-Recipient Immunity TransferNo drug interventionsNot AvailableNot Availablecompleted
NCT00001830
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsNo drug interventionstreatment1completed
NCT01028430
B Cell Repertoires in Chronic Lymphocytic Leukemia and AgingNo drug interventionsNot AvailableNot Availablecompleted
NCT00442130
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationNo drug interventionstreatment1completed
NCT01088048
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemiatreatment1completed
NCT02200848
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)treatment1terminated
NCT02251548
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemiatreatment2active_not_recruiting
NCT02677948
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment1 / 2withdrawn
NCT00276848
Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemiatreatment3completed
NCT00873457
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2completed
NCT00850057
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment1completed
NCT01393366
Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention StrategyNo drug interventionssupportive_careNot Availablecompleted
NCT00800566
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)treatment1withdrawn
NCT02758665
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLtreatment2completed
NCT04952974
B-cell Chronic Lymphoid Malignancies MarkersNo drug interventionsNot AvailableNot Availableunknown_status
NCT02264574
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)treatment3completed
NCT06043674
A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformationtreatment2recruiting
NCT05028374
COVID-19 VAX Booster Dosing in Patients With Hematologic MalignanciesNo drug interventionstreatment2completed
NCT04616274
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic LeukemiaNot AvailableNot Availablerecruiting
NCT02582320
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient ProgramNot AvailableNot Availablecompleted
NCT00794820
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontlinetreatment2completed
NCT02141282
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapytreatment2completed
NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphomatreatment2completed
NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignanciestreatment1completed
NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patientsprevention2terminated
NCT00828282
High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLLtreatment1completed
NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignanciestreatment2completed
NCT02445131
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)treatment2completed
NCT02034227
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemiatreatment1 / 2terminated
NCT01650727
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)treatment1completed
NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantNo drug interventionstreatment1terminated
NCT03529227
Gazyva Infusion Reaction InvestigationNo drug interventionsNot AvailableNot Availablerecruiting
NCT05465876
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLLtreatment2withdrawn
NCT01515176
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemiatreatment1 / 2completed
NCT03501576
Evaluation of Human Immune Responses Vaccination in Patients With LymphomaNot AvailableNot Availablerecruiting
NCT00801060
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expressiontreatment3active_not_recruiting
NCT03280160
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumabtreatment2unknown_status
NCT04657094
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemiatreatment2active_not_recruiting
NCT01011894
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Agetreatment2completed
NCT02110394
Ribomustin in the First Line Therapy of Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT01739491
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic LeukemiaNot AvailableNot Availablewithdrawn
NCT01539291
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)treatment3terminated
NCT00481091
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT01930162
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplantbasic_science2completed
NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemiatreatment2recruiting
NCT01488162
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplanttreatment2completed
NCT03513562
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutationstreatment2active_not_recruiting
NCT00167180
Post Transplant Donor Lymphocyte Infusiontreatment2terminated
NCT01610180
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)treatment2completed
NCT00022880
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemiatreatment1unknown_status
NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignanciestreatment2terminated
NCT01521689
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatmenttreatment2unknown_status
NCT01685892
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemiatreatment1completed
NCT03881592
Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their EffectivenessNo drug interventionsNot AvailableNot Availableunknown_status
NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancerstreatment1active_not_recruiting
NCT05197192
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLtreatment3recruiting
NCT05093192
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic LeukaemiaNo drug interventionsbasic_scienceNot Availablecompleted
NCT06362044
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanNo drug interventionsNot AvailableNot Availablerecruiting
NCT06547944
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment1active_not_recruiting
NCT01072240
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic LeukemiaNot AvailableNot Availablecompleted
NCT05147467
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLtreatment2recruiting
NCT04809467
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)treatment1 / 2active_not_recruiting
NCT00524667
HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemiatreatment2terminated
NCT06416267
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)No drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT00076401
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT01310101
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment2completed
NCT00283101
A Safety Study in Patients With Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT02619604
A Quality Improvement Approach to the Management of Chronic Lymphocytic LeukemiaNo drug interventionshealth_services_researchNot Availablecompleted
NCT01263704
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT04843904
Safe Accelerated Venetoclax Escalation in CLLtreatment1recruiting
NCT00290004
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1 / 2completed
NCT00504972
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell MalignanciesNo drug interventionstreatment1completed
NCT02424968
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphomatreatment2completed
NCT01010568
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT02315768
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.treatment1 / 2active_not_recruiting
NCT05099068
Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)No drug interventionsdiagnosticNot Availablerecruiting
NCT05037669
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphomatreatment1withdrawn
NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignanciestreatment2completed
NCT00055146
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT00854646
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)treatment1completed
NCT01724346
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment3completed
NCT01403246
Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)other1 / 2terminated
NCT04356846
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell LymphomaNo drug interventionstreatment1recruiting
NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord UnitNo drug interventionstreatment2terminated
NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignanciestreatment1terminated
NCT05694312
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLtreatment2recruiting
NCT01670812
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemiatreatment3unknown_status
NCT03195010
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaNo drug interventionssupportive_care2terminated
NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLtreatment1 / 2active_not_recruiting
NCT01024010
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKitreatment2completed
NCT00416910
Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemiatreatment3terminated
NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignanciestreatment1 / 2completed
NCT00234481
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemiatreatment1terminated
NCT00634881
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT00309881
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)treatment2completed
NCT01569295
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )treatment3completed
NCT05803395
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.No drug interventionsNot AvailableNot Availablerecruiting
NCT02892695
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphomatreatment1 / 2unknown_status
NCT00093314
HuMax-CD20 in Chronic Lymphocytic Leukemiatreatment1 / 2withdrawn
NCT03153514
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantationtreatment2terminated
NCT00543114
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLtreatment1terminated
NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaNo drug interventionstreatment1terminated
NCT00636155
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2terminated
NCT02518555
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT01657955
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemiatreatment3unknown_status
NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignanciestreatment2completed
NCT03019055
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B CellNo drug interventionstreatment1completed
NCT01002755
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT00419250
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemiatreatment1completed
NCT00754650
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemiatreatment2completed
NCT01110850
Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated WaterNo drug interventionsNot AvailableNot Availablecompleted
NCT05437250
National Acalabrutinib Observational StudyNot AvailableNot Availableactive_not_recruiting
NCT02456350
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignanciestreatment1unknown_status
NCT00918723
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1 / 2completed
NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxistreatment2completed
NCT01609023
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic LeukemiaNot AvailableNot Availablecompleted
NCT02144623
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemiatreatment0completed
NCT04964908
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT04682808
A Study of FCN-338 in Patients With Chronic CLL/SLLNo drug interventionstreatment1active_not_recruiting
NCT01716208
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphomatreatment2completed
NCT02015208
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT05371808
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:No drug interventionsNot AvailableNot Availablerecruiting
NCT01460238
Lipoprotein Lipase Expression in Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availablecompleted
NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carrierstreatment3unknown_status
NCT01944943
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemiatreatment2terminated
NCT04626843
Intermittent Fasting and CLL/SLLNo drug interventionstreatment1completed
NCT05899543
Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia PatientsNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT01133743
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT05404282
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)treatment1active_not_recruiting
NCT00984165
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell TransplantationNo drug interventionstreatment2terminated